Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: Is there any room for intervention?

British Journal of Haematology

Volumn 164, Issue 3, 2014, Pages 396-408

  Balduzzi, Adriana ^a   Di Maio, Lucia ^a   Silvestri, Daniela ^a,b   Songia, Simona ^b   Bonanomi, Sonia ^a   Rovelli, Attilio ^a   Conter, Valentino ^a   Biondi, Andrea ^a,b   Cazzaniga, Giovanni ^b   Valsecchi, Maria G ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Acute lymphoblastic leukaemia; Allogeneic transplantation; Childhood; Minimal residual disease; Relapse

Indexed keywords

CYTARABINE; FLUDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CUMULATIVE INCIDENCE OF RELAPSE; DONOR LYMPHOCYTE INFUSION; EVENT FREE SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; RISK REDUCTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE;

ACUTE LYMPHOBLASTIC LEUKAEMIA; ALLOGENEIC TRANSPLANTATION; CHILDHOOD; MINIMAL RESIDUAL DISEASE; RELAPSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 84892463285     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12639     Document Type: Article

References (56)

1. Bader, P., Hancock, J., Kreyenberg, H., Goulden, N.J., Niethammer, D., Oakhill, A., Steward, C.G., Handgretinger, R., Beck, J.F. & Klingebiel, T. (2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia, 16, 1668-1672.
2. Bader, P., Kreyenberg, H., Hoelle, W., Dueckers, G., Handgretinger, R., Lang, P., Kremens, B., Dilloo, D., Sykora, K.W., Schrappe, M., Niemeyer, C., Von Stackelberg, A., Gruhn, B., Henze, G., Greil, J., Niethammer, D., Dietz, K., Beck, J.F. & Klingebiel, T. (2004) Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? Journal of Clinical Oncology, 22, 1696-1705.
3. Bader, P., Kreyenberg, H., Henze, G.H., Eckert, C., Reising, M., Willasch, A., Barth, A., Borkhardt, A., Peters, C., Handgretinger, R., Sykora, K.W., Holter, W., Kabisch, H., Klingebiel, T., von Stackelberg, A. & ALL-REZ BFM Study Group. (2009) Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. Journal of Clinical Oncology, 27, 377-384.
4. Balduzzi, A., Valsecchi, M.G., Uderzo, C., De Lorenzo, P., Klingebiel, T., Peters, C., Stary, J., Felice, M.S., Magyarosy, E., Conter, V., Reiter, A., Messina, C., Gadner, H. & Schrappe, M. (2005) Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet, 366, 635-642.
5. Balduzzi, A., Bonanomi, S., Valsecchi, M.G., Gaipa, G., Perseghin, P., Songia, S., Maglia, O., Rossi, V., Motta, S., Di Maio, L., Dassi, M., Uderzo, C., Conter, V., Henze, G., von Stackelberg, A., Rovelli, A., Biondi, A. & Galimberti, S. (2011a) Autologous purified peripheral blood SCT in childhood low-risk relapsed ALL. Bone Marrow Transplantation, 46, 217-226.
6. Balduzzi, A., Galimberti, S., Valsecchi, M.G., Bonanomi, S., Conter, V., Barth, A., Rovelli, A., Henze, G., Biondi, A. & von Stackelberg, A. (2011b) Autologous purified peripheral blood stem cell transplantation compare to chemotherapy in childhood acute lymphoblastic leukemia after low-risk relapse. Pediatric Blood & Cancer, 57, 654-659.
7. Bethge, W.A., Hegenbart, U., Stuart, M.J., Storer, B.E., Maris, M.B., Flowers, M.E., Maloney, D.G., Chauncey, T., Bruno, B., Agura, E., Forman, S.J., Blume, K.G., Niederwieser, D., Storb, R. & Sandmaier, B.M. (2004) Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood, 103, 790-795.
8. Biagi, E., Rovelli, A., Balduzzi, A., De Lorenzo, P., Tagliabue, A. & Uderzo, C. (2000) TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission. Bone Marrow Transplantation, 26, 1260-1262.
9. Biondi, A., Schrappe, M., De Lorenzo, P., Castor, A., Lucchini, G., Gandemer, V., Pieters, R., Stary, J., Escherich, G., Campbell, M., Li, C.K., Vora, A., Aricò, M., Röttgers, S., Saha, V. & Valsecchi, M.G. (2012) Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, InterGroup Study. The Lancet Oncology, 13, 936-945.
10. Borgmann, A., von Stackelberg, A., Hartmann, R., Ebell, W., Klingebiel, T., Peters, C., Henze, G. & Berlin-Frankfurt-Münster Relapse Study Group. (2003) Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. Blood, 101, 3835-3839.
11. Cazzaniga, G., Valsecchi, M.G., Gaipa, G., Conter, V. & Biondi, A. (2011) Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia. British Journal of Haematology, 155, 45-52.
12. Clavio, M., Venturino, C., Pierri, I., Garrone, A., Miglino, M., Canepa, L., Balleari, E., Balocco, M., Michelis, G.L., Ballerini, F. & Gobbi, M. (2004) Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Annals of Hematology, 83, 696-703.
13. Collins, R.H. Jr, Goldstein, S., Giralt, S., Levine, J., Porter, D., Drobyski, W., Barrett, J., Johnson, M., Kirk, A., Horowitz, M. & Parker, P. (2000) Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplantation, 26, 511-516.
14. Conter, V., Bartram, C.R., Valsecchi, M.G., Schrauder, A., Panzer-Grümayer, R., Möricke, A., Aricò, M., Zimmermann, M., Mann, G., De Rossi, G., Stanulla, M., Locatelli, F., Basso, G., Niggli, F., Barisone, E., Henze, G., Ludwig, W.D., Haas, O.A., Cazzaniga, G., Koehler, R., Silvestri, D., Bradtke, J., Parasole, R., Beier, R., van Dongen, J.J., Biondi, A. & Schrappe, M. (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, 115, 3206-3214.
15. Deeg, H.J. & Antin, J.H. (2006) The clinical spectrum of acute graft-versus-host disease. Seminars in Hematology, 43, 24-31.
16. Eapen, M., Raetz, E., Zhang, M.J., Muehlenbein, C., Devidas, M., Abshire, T., Billett, A., Homans, A., Camitta, B., Carroll, W.L., Davies, S.M., Children's Oncology Group & Center for International Blood and Marrow Transplant Research. (2006a) Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood, 107, 4961-4967.
17. Eapen, M., Rubinstein, P., Zhang, M.J., Camitta, B.M., Stevens, C., Cairo, M.S., Davies, S.M., Doyle, J.J., Kurtzberg, J., Pulsipher, M.A., Ortega, J.J., Scaradavou, A., Horowitz, M.M. & Wagner, J.E. (2006b) Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. Journal of Clinical Oncology, 24, 145-151.
18. Eapen, M., Rubinstein, P., Zhang, M.J., Stevens, C., Kurtzberg, J., Scaradavou, A., Loberiza, F.R., Champlin, R.E., Klein, J.P., Horowitz, M.M. & Wagner, J.E. (2007) Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet, 369, 1947-1954.
19. Eckert, C., Biondi, A., Seeger, K., Cazzaniga, G., Hartmann, R., Beyermann, B., Pogodda, M., Proba, J. & Henze, G. (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet, 358, 1239-1241.
20. Eckert, C., von Stackelberg, A., Seeger, K., Groeneveld, T.W., Peters, C., Klingebiel, T., Borkhardt, A., Schrappe, M., Escherich, G. & Henze, G. (2012) Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96. European Journal of Cancer, 49, 1346-1355.
21. Filipovich, A.H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J.R., Lee, S.J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., Cowen, E.W., Dinndorf, P., Farrell, A., Hartzman, R., Henslee-Downey, J., Jacobsohn, D., McDonald, G., Mittleman, B., Rizzo, J.D., Robinson, M., Schubert, M., Schultz, K., Shulman, H., Turner, M., Vogelsang, G. & Flowers, M.E. (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation, 11, 945-956.
22. Flohr, T., Schrauder, A., Cazzaniga, G., Panzer-Grümayer, R., van der Velden, V., Fischer, S., Stanulla, M., Basso, G., Niggli, F.K., Schäfer, B.W., Sutton, R., Koehler, R., Zimmermann, M., Valsecchi, M.G., Gadner, H., Masera, G., Schrappe, M., van Dongen, J.J., Biondi, A., Bartram, C.R. & International BFM Study Group (I-BFM-SG). (2008) Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 22, 771-782.
23. Freyer, D.R., Devidas, M., La, M., Carroll, W.L., Gaynon, P.S., Hunger, S.P. & Seibel, N.L. (2011) Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood, 117, 3010-3015.
24. Fronkova, E., Muzikova, K., Mejstrikova, E., Kovac, M., Formankova, R., Sedlacek, P., Hrusak, O., Stary, J. & Trka, J. (2008) B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. Bone Marrow Transplantation, 42, 187-196.
25. Gray, R.J. (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. The Annals of Statistics, 16, 1141-1154.
26. Hunger, S.P., Lu, X., Devidas, M., Camitta, B.M., Gaynon, P.S., Winick, N.J., Reaman, G.H. & Carroll, W.L. (2012) Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. Journal of Clinical Oncology, 30, 1663-1669.
27. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
28. Klingebiel, T., Bader, P. & EBMT Paediatric Working Party. (2008) Delayed lymphocyte infusion in children given SCT. Bone Marrow Transplantation, 41(Suppl. 2), S23-S26.
29. Klingebiel, T., Cornish, J., Labopin, M., Locatelli, F., Darbyshire, P., Handgretinger, R., Balduzzi, A., Owoc-Lempach, J., Fagioli, F., Or, R., Peters, C., Aversa, F., Polge, E., Dini, G. & Rocha, V. (2010) Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood, 115, 3437-3446.
30. Knechtli, C.J., Goulden, N.J., Hancock, J.P., Grandage, V.L., Harris, E.L., Garland, R.J., Jones, C.G., Rowbottom, A.W., Hunt, L.P., Green, A.F., Clarke, E., Lankester, A.W., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92, 4072-4079.
31. Lankester, A.C., Bierings, M.B., van Wering, E.R., Wijkhuijs, A.J., de Weger, R.A., Wijnen, J.T., Vossen, J.M., Versluys, B., Egeler, R.M., van Tol, M.J., Putter, H., Révész, T., van Dongen, J.J., van der Velden, V.H. & Schilham, M.W. (2010) Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia, 24, 1462-1469.
32. Leung, W., Pui, C.H., Coustan-Smith, E., Yang, J., Pei, D., Gan, K., Srinivasan, A., Hartford, C., Triplett, B.M., Dallas, M., Pillai, A., Shook, D., Rubnitz, J.E., Sandlund, J.T., Jeha, S., Inaba, H., Ribeiro, R.C., Handgretinger, R., Laver, J.H. & Campana, D. (2012) Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood, 120, 468-472.
33. Lutz, C., Massenkeil, G., Nagy, M., Neuburger, S., Tamm, I., Rosen, O., Dörken, B. & Arnold, R. (2008) A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 41, 805-812.
34. Marubini, E. & Valsecchi, M.G. (1995) The Cox Regression Model -Analysing Survival Data from Clinical Trials and Observational Studies, pp. 171-222. John Wiley, Chichester, UK.
35. McCarthy, A.J., Pitcher, L.A., Hann, I.M. & Oakhill, A. (1999) FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Medical and Pediatric Oncology, 32, 411-415.
36. Meisel, R., Klingebiel, T., Dilloo, D. & German/Austrian Pediatric Registry for Stem Cell Transplantation. (2013) Peripheral blood stem cells versus bone marrow in pediatric unrelated donor stem cell transplantation. Blood, 121, 863-865.
37. Miller, J.S., Warren, E.H., van den Brink, M.R., Ritz, J., Shlomchik, W.D., Murphy, W.J., Barrett, A.J., Kolb, H.J., Giralt, S., Bishop, M.R., Blazar, B.R. & Falkenburg, J.H. (2010) NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: graft-versus-Tumor/Leukemia Reaction. Biology of Blood and Marrow Transplantation, 16, 565-586.
38. Nemecek, E.R., Ellis, K., He, W., Bunin, N.J., Bajwa, R.S., Cheerva, A., Cairo, M.S., Dvorak, C., Duval, M., Davies, S., Eapen, M., Gross, T.G., Hussein, A.A., MacMillan, M.L., Mehta, P.A., Pulsipher, M.A., Seber, A., Woolfrey, A.E., Frangoul, H.A. & Carpenter, P.A. (2011) Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remission. Biology of Blood and Marrow Transplantation, 17, 1833-1840.
39. Oliansky, D.M., Camitta, B., Gaynon, P., Nieder, M.L., Parsons, S.K., Pulsipher, M.A., Dillon, H., Ratko, T.A., Wall, D., McCarthy, P.L. Jr & Hahn, T. (2012) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biology of Blood and Marrow Transplantation, 18, 979-981.
40. Parker, C., Waters, R., Leighton, C., Hancock, J., Sutton, R., Moorman, A.V., Ancliff, P., Morgan, M., Masurekar, A., Goulden, N., Green, N., Révész, T., Darbyshire, P., Love, S. & Saha, V. (2010) Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet, 376, 2009-2017.
41. Peters, C., Schrauder, A., Schrappe, M., von Stackelberg, A., Stary, J., Yaniv, I., Gadner, H., Klingebiel, T. & BFM Study Group, the IBFM-Study Group and the Paediatric Disease Working Party of the EBMT. (2005) Allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia: the BFM/IBFM/EBMT concepts. Bone Marrow Transplantation, 35(Suppl. 1), S9-S11.
42. Pieters, R., Schrappe, M., De Lorenzo, P., Hann, I., De Rossi, G., Felice, M., Hovi, L., LeBlanc, T., Szczepanski, T., Ferster, A., Janka, G., Rubnitz, J., Silverman, L., Stary, J., Campbell, M., Li, C.K., Mann, G., Suppiah, R., Biondi, A., Vora, A. & Valsecchi, M.G. (2007) A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet, 370, 240-250.
43. Pui, C.H., Mullighan, C.G., Evans, W.E. & Relling, M.V. (2012) Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood, 120, 1165-1174.
44. Pulsipher, M.A., Bader, P., Klingebiel, T. & Cooper, L.J. (2009) Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biology of Blood and Marrow Transplantation, 15(Suppl. 1), 62-71.
45. Quarello, P., Berger, M., Rivetti, E., Galletto, C., Masetti, R., Manicone, R., Barisone, E., Pession, A. & Fagioli, F. (2012) FLAG-liposomal doxorubicin (Myocet) regimen for refractory or relapsed acute leukemia pediatric patients. Journal of Pediatric Hematology/Oncology, 34, 208-216.
46. Raiola, A.M., Van Lint, M.T., Lamparelli, T., Gualandi, F., Mordini, N., Berisso, G., Bregante, S., Frassoni, F., Sessarego, M., Fugazza, G., Di Stefano, F., Pitto, A. & Bacigalupo, A. (2000) Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. British Journal of Haematology, 109, 716-721.
47. Ruggeri, A., Michel, G., Dalle, J.H., Caniglia, M., Locatelli, F., Campos, A., de Heredia, C.D., Mohty, M., Hurtado, J.M., Bierings, M., Bittencourt, H., Mauad, M., Purtill, D., Cunha, R., Kabbara, N., Gluckman, E., Labopin, M., Peters, C. & Rocha, V. (2012) Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis. Leukemia, 26, 2455-2461.
48. Schilham, M.W., Balduzzi, A. & Bader, P. (2005) Is there a role for minimal residual disease levels in the treatment of ALL patients who receive allogeneic stem cells? Bone Marrow Transplantation, 35(Suppl. 1), S49-S52.
49. Schrappe, M., Valsecchi, M.G., Bartram, C.R., Schrauder, A., Panzer-Grümayer, R., Möricke, A., Parasole, R., Zimmermann, M., Dworzak, M., Buldini, B., Reiter, A., Basso, G., Klingebiel, T., Messina, C., Ratei, R., Cazzaniga, G., Koehler, R., Locatelli, F., Schäfer, B.W., Aricò, M., Welte, K., van Dongen, J.J., Gadner, H., Biondi, A. & Conter, V. (2011) Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 118, 2077-2084.
50. Schrappe, M., Hunger, S.P., Pui, C.H., Saha, V., Gaynon, P.S., Baruchel, A., Conter, V., Otten, J., Ohara, A., Versluys, A.B., Escherich, G., Heyman, M., Silverman, L.B., Horibe, K., Mann, G., Camitta, B.M., Harbott, J., Riehm, H., Richards, S., Devidas, M. & Zimmermann, M. (2012) Outcomes after induction failure in childhood acute lymphoblastic leukemia. The New England Journal of Medicine, 366, 1371-1381.
51. Sedlacek, P., Formankova, R., Mejstrikova, E., Keslova, P., Hubacek, P., Dobrovolna, M., Vrana, M., Kupkova, L., Pittrova, H. & Stary, J. (2008) Allogeneic stem cell transplantation in children with leukemia using human leukocyte antigen-mismatched unrelated donors. Pediatric Transplantation, 12, 24-31.
52. Sramkova, L., Muzikova, K., Fronkova, E., Krejci, O., Sedlacek, P., Formankova, R., Mejstrikova, E., Stary, J. & Trka, J. (2007) Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia. Pediatric Blood & Cancer, 48, 93-100.
53. Tallen, G., Ratei, R., Mann, G., Kaspers, G., Niggli, F., Karachunsky, A., Ebell, W., Escherich, G., Schrappe, M., Klingebiel, T., Fengler, R., Henze, G. & von Stackelberg, A. (2010) Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. Journal of Clinical Oncology, 28, 2339-2347.
54. van der Velden, V.H., Cazzaniga, G., Schrauder, A., Hancock, J., Bader, P., Panzer- Grumayer, E.R., Flohr, T., Sutton, R., Cave, H., Madsen, H.O., Cayuela, J.M., Trka, J., Eckert, C., Foroni, L., Zur Stadt, U., Beldjord, K., Raff, T., van der Schoot, C.E., van Dongen, J.J. & European Study Group on MRD detection in ALL (ESG-MRD-ALL). (2007) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia, 21, 604-611.
55. Wachowiak, J., Sykora, K.W., Cornish, J., Chybicka, A., Kowalczyk, J.R., Gorczyńska, E., Choma, M., Grund, G., Peters, C. & EBMT Pediatric Diseases Working Party. (2011) Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplantation, 46, 1510-1518.
56. Zhang, M.J., Davies, S.M., Camitta, B.M., Logan, B., Tiedemann, K., Eapen, M. & Thiel, E.L. (2012) Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. Biology of Blood and Marrow Transplantation, 18, 1204-1210.